Going into 2024, hopes were moderately high for dealmaking and the wider financial landscape in pharma. M&A and IPOs were picking up, offering investors the exit opportunities they need. But the second quarter of the year took several steps back, with fairly significant drops in the number and value of deals taking place, and just three companies hitting the public markets.
Fortunately, the quarter wasn’t without its successes. Private funding had a strong showing, giving biotechs a chance to extend their cash runways.
The Quarterly Round Up infographic provides a concise overview of the shifting landscape in Q2.
Key questions answered:
- How significant was the dip in deal volume and values during Q2?
- Which deals topped the charts this quarter?
- With a surge in VC investment, where is the money flowing?
- How did the number of IPOs and the total cash raised change from last quarter to this one?
